Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Glofitamab, Venetoclax and Lenalidomide in Newly Diagnosed High Risk Mantle Cell Lymphoma
NCT05861050Phase 2Recruiting
- Sponsor
- City of Hope
- Start
- Aug 2023
- Primary completion
- Feb 2027
- Modality
- Antibody Conjugates, Small Molecules, Bispecific Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of glofitamab, venetoclax, lenalidomide in mantle cell lymphoma (MCL), sponsored by City of Hope. Started Aug 2023; status: recruiting.
02
Drugs
glofitamabvenetoclaxlenalidomide
03
Conditions
mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on NCT05861050.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05861050.